Condition: Juvenile Idiopathic Arthritis · Sponsor: Eli Lilly and Company
The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.
This description comes directly from the study's public registry record.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
Always discuss trial participation with your own doctor first.
| Instituto CAICI SRL | Rosario, Argentina | Recruiting |
| Centro de Investigaciones Médicas Tucuman | SAN M. de Tucuman, Argentina | Recruiting |
| Royal Children's Hospital | Melbourne, Australia | Not Yet Recruiting |
| Perth Children's Hospital | Perth, Australia | Not Yet Recruiting |
| The Children's Hospital at Westmead | Westmead, Australia | Active Not Recruiting |
| Landeskrankenhaus Bregenz | Bregenz, Austria | Completed |
| Cliniques universitaires Saint-Luc | Brussels, Belgium | Completed |
| UZ Gent | Ghent, Belgium | Recruiting |
| UZ Leuven | Leuven, Belgium | Recruiting |
| Faculdade de Medicina da UNESP | Botucatu, Brazil | Recruiting |
| Universidade Federal de Sao Paulo | São Paulo, Brazil | Recruiting |
| Instituto da Crianca do Hospital das Clinicas da FMUSP | São Paulo, Brazil | Recruiting |
+ 67 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03773965